GlaxoSmithKline to present at ERS International Congress
Presentations include Fulfil, a combination inhaler for patients who have chronic obstructive pulmonary disease. There will also be updates from the Salford Lung Study, which evaluated the efficacy and safety of Relvar Ellipta compared to traditional care and treatments.
The presentations will be given at the European Respiratory Society (ERS) International Congress, which will be held in London Sept. 3-7. The congress will feature over 30 abstracts from GSK.
“We are delighted that this year’s ERS is taking place in our home city of London,” Neil Barnes, global franchise medical head, said. “As the largest respiratory scientific meeting in the world, the ERS provides a great forum to share and debate the ongoing research we are conducting to advance respiratory science and help patients with lung disease. Our approach to research starts with our understanding that each patient is different. That is why our discovery and development work is focused on understanding patient types and our clinical programs on generating evidence that supports a clinician’s ability to select the right medicine for the right patients. This has resulted in GSK’s broad portfolio of respiratory medicines, with a treatment option available at each stage of disease as defined in international guidelines for asthma and COPD.”
Organizations in this story
GlaxoSmithKline 5 Crescent Dr Philadelphia, PA 19112